Depomed takes $240.5m in PDL royalty deal to fund acquisitions
This article was originally published in Scrip
Executive Summary
Depomed raised $240.5m without diluting investors or adding debt to its balance sheet by selling its type 2 diabetes-related royalty streams to PDL BioPharma.